Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements are consistent with the provided Beyfortus labeling excerpts (active ingredient naming and injection formulation). However, the excipients claim is not supported/covered by the provided label excerpts, and no boxed warning/contraindication/warnings/usage-dose details are assessed against the specific AI claims beyond formulation and general indication context.
Category Scores
Accurate Statements
Beyfortus contains the monoclonal antibody nirsevimab as its active ingredient.
Label lists active ingredient as nirsevimab-alip (Sections 1 and 2/4 context; excipient/interaction sections reference nirsevimab-alip).
The key ingredient listed for Beyfortus is nirsevimab.
Label repeatedly references nirsevimab-alip as the monoclonal antibody (e.g., Sections 7, 12).
Beyfortus is provided as a solution for injection.
Section 3: 'BEYFORTUS is a clear to opalescent, colorless to yellow solution' and lists injection presentations.
Unsupported Statements
Specific inactive ingredients (excipients) are not detailed in the provided information.
The label excerpts provided in the prompt do not address excipient details directly; therefore this statement is not verifiable as supported by the supplied label excerpts.
Beyfortus is built around nirsevimab, whose purpose is tied to its action against RSV (respiratory syncytial virus).
While the indication is RSV prevention (Section 1), the statement is interpretive ('built around' and 'whose purpose is tied to its action against RSV') and is not a direct on-label phrasing supported by a specific excerpt in the provided label text.
Contradictions
Important Omissions
No evaluation of dosing/administration specifics relative to the AI claims (e.g., weight-based first-season dosing, second-season 2×100 mg, IM administration, timing by season, or additional dose after cardiac surgery with cardiopulmonary bypass).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are largely product identity/formulation-related and do not include contraindications, warnings, dosing, or safety instructions that could directly lead to misuse. One excipients-related statement is unverifiable from provided excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One statement about excipients is not supported/covered by the provided label excerpts; one RSV mechanism/purpose statement is interpretive rather than directly supported by a specific label excerpt.
Suggested Improvement
Limit claims to label-supported facts from the provided excerpts (e.g., active ingredient nirsevimab-alip, clear-to-opalescent solution for injection, indication for RSV LRTD prevention, and avoid unverifiable statements about excipients or mechanistic phrasing not directly quoted/contained in the excerpts).